Oral contraceptives

Oral contraceptives has been studied in 119 papers since 2001: 8 trials and 81 observational studies in people, 1 in animals, 28 reviews; 49 in the past year. The newest paper, Nov 16, 2026: “Bone biomarker concentrations at baseline and 24 h after resistance and interval running exercise in eumenorrheic females and oral contraceptive users”.

Intervention

119 papers study it89 findingsUpdated

6 new papers in 30 daysSee all 119 papers on oral contraceptives

At a glance

Independent labs found the same change in people. 53 independent labs in 18 countries; 7 trials, none about aging, 4 with no results posted.

“Pretreatment with oral contraceptives likely has little effect on the ovulation and live birth rate compared with immediate treatment.”
Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOSThe Journal of clinical endocrinology and metabolism2016doi:10.1210/jc.2016-1659

6 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 53 independent labs in 18 countries
  • 6 findings against
  • 7 trials, none about aging, 4 with no results posted
  • Funders: National Cancer Institute and others
  • 6 of 81 findings with company ties
  • Human trial8
  • Humans81
  • Animals1

Studies in people

5 studies gave oral contraceptives to people and measured what changed.

What changedDesignPeopleSource

up: Increases HDL particle concentration

up: Increases small LDL particles

up: Increases cholesterol efflux capacityadjusted ratio of geometric means 1.08, 95% CI 0.99-1.17

Randomized trial24 weeks180 peopleWomenHyperandrogenic PCOS and elevated BMIEuropean journal of endocrinology, Aug 3, 2026

up: Improves Montreal Cognitive AssessmentB=.090, p=.033

up: Improves working memoryB=.094, p=.017

Treated cohort461 peopleWomenolder womenOlder adults; Postmenopausal women; baseline cognitive performance accounting for age, education, APOE ε4 carrier status, and raceGSA 2024 abstract, Dec 31, 2024

down: Decreases distal tibia trabecular density

Randomized trial12 months90 peopleWomen18–25 yearsWithin-group change in oral contraceptive users not consuming prunesCurrent developments in nutrition, Jul 18, 2024

up: Increases weight loss2.87 kg vs 1.36 kg, p < 0.001

Trial4 weeks19 peopleWomen18-25 yearsFollowing 500-kcal reduction diet interventionClinical nutrition ESPEN, Feb 17, 2022

no change: Has no effect on live birth rateovulation 45% and live birth 8.5% vs 44.7% and 10.2%

Randomized trial187 peopleWomen18-40 yearsOverweight/obese and infertile with PCOSThe Journal of clinical endocrinology and metabolism, May 12, 2016

What did studies of oral contraceptives find?

33

Studies of oral contraceptives measured 33 outcomes, among them breast cancer, anti-Müllerian hormone and cholesterol efflux capacity.

Breast cancer

no changein humans2HR 0.9–0.99

2 studies
  1. Oral contraceptives were not clearly linked with breast cancer in humans (BRCA1 carriers) (HR 0.90, 95% CI 0.77-1.05).

    “oral contraceptive use was not associated with breast cancer risk (HR = 0.90, 95% CI 0.77-1.05, p = 0.2)”

    HumansBRCA1 carriersfemalesn = 990

    Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant

    Breast cancer (Tokyo, Japan)

  2. Oral contraceptives were not clearly linked with breast cancer in humans (previous use) (HR 0.99 (95% CI 0.92–1.05)).

    “In contrast, previous use showed no association (HR = 0.99, 95% CI: 0.92–1.05).”

    Humansprevious use

    Breast cancer risk during oral contraceptive use in women with high polygenic risk

    Breast cancer research : BCR

More on Breast cancer

Anti-Müllerian hormone

downin humans2

2 studies
  1. Oral contraceptives are linked with lower anti-Müllerian hormone in humans (current use compared with never use) (41.5% lower (95% CI −49.9 to −31.4%)).

    “current oral contraceptive use was associated with 41.5% (95% CI ‒49.9 to ‒31.4%) lower AMH levels”

    Humanscurrent use compared with never usefemales

    Exploring the association between lifestyle factors and anti-Müllerian hormone concentration and rate of decline

    Reproductive biomedicine online

  2. Oral contraceptives are linked with lower anti-Müllerian hormone in humans (compared with never use) (40% lower, P < 0.0001).

    “Current oral contraceptive (OC) use and current/former smoking were associated with lower AMH concentration than never use (40% and 12% lower, respectively, P < 0.0001).”

    Humanscompared with never usefemales

    Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal Women

    The Journal of clinical endocrinology and metabolism

More on Anti-Müllerian hormone

Cholesterol efflux capacity

upin humans1

1 study
  1. Oral contraceptives increase cholesterol efflux capacity in humans (hyperandrogenic PCOS and elevated BMI) (adjusted ratio of geometric means 1.08, 95% CI 0.99-1.17).

    “Cholesterol efflux capacity increased in the OCP arm”

    Human trialhyperandrogenic PCOS and elevated BMI24 weeks

    Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome

    European journal of endocrinology

More on Cholesterol efflux capacity

Small LDL particles

upin humans1

1 study
  1. Oral contraceptives increase small LDL particles in humans (hyperandrogenic PCOS and elevated BMI).

    “while atherogenic small LDL-P increased slightly”

    Human trialhyperandrogenic PCOS and elevated BMI24 weeks

    Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome

    European journal of endocrinology

More on Small LDL particles

HDL particle concentration

upin humans1

1 study
  1. Oral contraceptives increase HDL particle concentration in humans (hyperandrogenic PCOS and elevated BMI).

    “HDL-P concentration increased in the OCP and OCP + metformin arms”

    Human trialhyperandrogenic PCOS and elevated BMI24 weeks

    Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome

    European journal of endocrinology

More on HDL particle concentration

Subfoveal choroidal thickness

no changein humans1

1 study
  1. Oral contraceptives were not clearly linked with subfoveal choroidal thickness in humans (β=5.45 μm; 95% CI, -4.58 to 15.48; P=0.287).

    “oral contraceptive use was not associated with either subfoveal choroidal thickness (β=5.45 μm; 95% CI, -4.58 to 15.48; P=0.287) or central macular thickness”

    Humanseyefemalesn = 5,886

    Impact of menopause on subfoveal choroidal thickness: population-based evidence from the 2017 to 2021 KNHANES

    Menopause (New York, N.Y.)

More on Subfoveal choroidal thickness

Soluble Klotho

downin humans1

1 study
  1. Oral contraceptives are linked with lower soluble Klotho in women taking estrogen-containing oral contraceptives compared with peers.

    “Women taking estrogen-containing oral contraceptives had lower sKlotho concentrations than their peers.”

    Humansin women taking estrogen-containing oral contraceptives compared with peersestrogen-containingfemales

    Age- and sex-specific reference values for phosphate homeostasis parameters-fibroblast growth factor 23 and soluble Klotho

    Clinical kidney journal

More on Soluble Klotho

Cognitive function

upin humans1

1 study
  1. Oral contraceptives are linked with better cognitive function in humans.

    “exogenous hormone use is associated with reduced dementia risk and better cognitive function”

    Humansfemalesn = 233,896

    Associations of oral contraceptives and hormone replacement therapy with incident dementia risk: a population-based cohort study

    Translational psychiatry

More on Cognitive function

Osteoporosis

downin humans1

1 study
  1. Oral contraceptives are linked with less osteoporosis in humans.

    “while OC use was protective.”

    Humansfemalesn = 49,885

    Female reproductive factors, genetic susceptibility and incident osteoporosis risk

    Climacteric : the journal of the International Menopause Society

More on Osteoporosis

Phonemic fluency

upin humans1

1 study
  1. Oral contraceptives are linked with better phonemic fluency in humans (0.07, 95% CI 0.06, 0.08).

    “oral contraceptive use (0.07, 95% CI 0.06,0.08), and cycle lengths of 35+ days (0.1, 95% CI 0.1,0.1) were associated with less declines over 25 years.”

    Humans25-year follow-upfemalesn = 1,398

    The role of hormonal and reproductive events on cognitive aging in a cohort of female civil servants: The Whitehall II Study

    AAIC 2025 abstract

Distal tibia trabecular density

downin humans1

1 study
  1. Oral contraceptives decrease distal tibia trabecular density in humans Within-group change in oral contraceptive users not consuming prunes.

    “Trabecular density of the distal tibia as measured by peripheral quantitative computed tomography decreased from baseline to 12 mo within the OC group only”

    Human trialWithin-group change in oral contraceptive users not consuming prunesdistal tibia12 monthsfemales

    Prunes May Blunt Adverse Effects of Oral Contraceptives on Bone Health in Young Adult Women: A Randomized Clinical Trial

    Current developments in nutrition

Weight loss

upin humans1

1 study
  1. Oral contraceptives increase weight loss in humans following 500-kcal reduction diet intervention (2.87 kg vs 1.36 kg, p < 0.001).

    “COC group lost more weight (2.87 kg) than NHC group (1.36 kg) (p < 0.001).”

    Human trialfollowing 500-kcal reduction diet intervention4 weeksfemalesn = 19

    Effect of oral contraceptive use on weight loss and body composition following low-calorie diet intervention

    Clinical nutrition ESPEN

Live birth rate

no changein humans1

1 study
  1. Oral contraceptives showed no clear effect on live birth rate in humans (overweight/obese and infertile with PCOS) (ovulation 45% and live birth 8.5% vs 44.7% and 10.2%).

    “Pretreatment with oral contraceptives likely has little effect on the ovulation and live birth rate compared with immediate treatment.”

    Human trialoverweight/obese and infertile with PCOSfemales

    Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS

    The Journal of clinical endocrinology and metabolism

All 33

What is oral contraceptives linked with?

39

Studies link oral contraceptives with 39 measures, most often breast cancer (7 studies), ovarian cancer (6) and mortality (2).

Breast cancer

upin humans4downin humans2mixedin humans1HR 0.8–1.21

7 studies
  1. Oral contraceptives are linked with a lower risk of breast cancer in humans (BRCA2 carriers) (HR 0.80, 95% CI 0.65-0.99).

    “oral contraceptive use was associated with reduced breast cancer risk (HR = 0.80, 95% CI 0.65-0.99, p = 0.04)”

    HumansBRCA2 carriersfemalesn = 687

    Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant

    Breast cancer (Tokyo, Japan)

  2. Oral contraceptives are linked with a lower risk of breast cancer in humans (Italian women undergoing integrated breast imaging diagnostics).

    “Conversely, an unexpected inverse association was assessed for menstrual irregularities, hyperlipidaemia, and oral contraceptive use.”

    HumansItalian women undergoing integrated breast imaging diagnosticsfemales

    Real-World Evidence for Breast Cancer Risk Stratification: Insights from the P.I.N.K. Study

    Cancers

  3. Oral contraceptives are linked with a higher risk of breast cancer in humans (current use) (HR 1.21 (95% CI 1.03–1.41)).

    “Current use of OC was associated with an increased risk of breast cancer, with a HR of 1.21 (95% CI: 1.03–1.41).”

    Humanscurrent use

    Breast cancer risk during oral contraceptive use in women with high polygenic risk

    Breast cancer research : BCR

  4. Oral contraceptives are linked with a higher risk of breast cancer in humans (ER+ breast cancer, in Latinas).

    “ever versus never OC use increased risk only in Latinas”

    HumansER+ breast cancer, in Latinasbreastfemales

    Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: The multiethnic cohort study

    International journal of cancer

  5. Oral contraceptives raise the risk of breast cancer in humans (OR=2.01).

    “OCP use (OR=2.01)”

    Reviewfemales

    Comprehensive Meta-analysis of Risk Factors for Breast Cancer among Indian Women

    Journal of mid-life health

  6. Oral contraceptives are associated with breast cancer in humans.

    “use of oral contraceptives, status menopausal, smoking, alcohol consumption, lifestyle, and genetics factors are significantly linked to breast cancer.”

    Reviewfemales

    Risk factors for breast cancer in women: an update review

    Medical oncology (Northwood, London, England)

  7. Oral contraceptives are associated with breast cancer in humans (Current or recent use).

    “Current or recent oral contraceptive use is associated with a higher risk of cardiovascular disease (mainly among smokers), melanoma, and breast cancer”

    ReviewCurrent or recent usefemales

    Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses' Health Study

    American journal of public health

More on Breast cancer

Ovarian cancer

downin humans6HR 0.57–0.75

6 studies
  1. Oral contraceptives are linked with a lower risk of ovarian cancer in humans (BRCA2 carriers) (HR 0.57, 95% CI 0.35-0.94).

    “Oral contraceptive use was associated with a decrease in the risk of ovarian cancer in BRCA2 carriers (HR = 0.57, 95% CI 0.35-0.94, p = 0.028)”

    HumansBRCA2 carriersfemalesn = 687

    Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant

    Breast cancer (Tokyo, Japan)

  2. Oral contraceptives are linked with a lower risk of ovarian cancer in humans.

    “oral contraceptive use for ≥1 year were also associated with reduced risk.”

    Humans≥1 yearfemales

    Reproductive history, hormonal exposure, and ovarian cancer risk in post-menopausal women: evidence from a nationwide Korean cohort

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

  3. Oral contraceptives are associated with ovarian cancer in humans (Premenopausal women) (HR 0.75, 95% CI 0.61–0.93).

    “Breastfeeding for 12 months or longer and oral contraceptive use for 1 year or longer were associated with lower risk in premenopausal women”

    HumansPremenopausal womenoral1 year or longerfemalesn = 932,637

    Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older

    JAMA network open

  4. Oral contraceptives are associated with ovarian cancer in humans (vs. controls without cancer) (p < 0.001).

    “whereas full-term pregnancy (p 0.001), breastfeeding (p 0.001), and oral contraceptive use (p 0.001) were less frequent.”

    Humansvs. controls without cancerfemales

    Predictive informativeness of risk factors for the development of ovarian cancer of different histological types: a randomized study

    Kazan medical journal

  5. Oral contraceptives are linked with a lower risk of ovarian cancer in humans (P = 0.79 for trend).

    “However, we observed no such attenuation in the oral contraceptive-associated risk reductions (P = 0.79 for trend in HR with increasing age).”

    Humansfemalesn = 310,290

    Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

  6. Oral contraceptives are associated with ovarian cancer in humans (Current or recent use).

    “and a lower risk of colorectal and ovarian cancer.”

    ReviewCurrent or recent usefemales

    Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses' Health Study

    American journal of public health

More on Ovarian cancer

Mortality

downin humans2HR 0.53

2 studies
  1. Oral contraceptives are linked with a lower risk of mortality in women with heart failure.

    “Among women with HF, OC, and MHT use were associated with lower mortality”

    Humansin women with heart failurefemales

    Reproductive history, hormonal exposure, and risk of heart failure in postmenopausal women: a Korean nationwide study

    European heart journal

  2. Oral contraceptives are linked with a lower risk of mortality in humans (HR 0.53, 95% CI 0.37-0.76).

    “those using for >5 years had adjusted hazard ratios of 0.53 (95% CI, 0.37-0.76) for all-cause”

    Humans>5 yearsfemalesn = 19,275

    Association of oral contraceptive use with mortality: Findings from NHANES

    Maturitas

Alzheimer's disease

downin humans1upin humans1HR 0.767

2 studies
  1. Oral contraceptives are linked with a lower risk of Alzheimer's disease in humans (HR 0.767, 95% CI 0.659-0.893).

    “Alzheimer's disease (AD) (HR [95%CI], 0.767 [0.659-0.893]) and vascular dementia (VaD) (HR [95%CI], 0.735 [0.578-0.934])”

    Humansfemalesn = 233,896

    Associations of oral contraceptives and hormone replacement therapy with incident dementia risk: a population-based cohort study

    Translational psychiatry

  2. Oral contraceptives are linked with a higher risk of Alzheimer's disease in humans.

    “Oral contraceptive use was also associated with an increased risk of AD.”

    Humansfemales

    Menstrual and reproductive factors and risk of Alzheimer's disease in elderly women: a cohort study in Eastern China

    Scientific reports

More on Alzheimer's disease

Dementia

downin humans2HR 0.806–0.9

2 studies
  1. Oral contraceptives are linked with a lower risk of dementia in humans (HR 0.806, 95% CI 0.724-0.897).

    “OC use was associated with reduced risks of all-cause dementia (ACD) (HR [95% CI], 0.806 [0.724-0.897])”

    Humansfemalesn = 233,896

    Associations of oral contraceptives and hormone replacement therapy with incident dementia risk: a population-based cohort study

    Translational psychiatry

  2. Oral contraceptives are linked with a lower risk of dementia in humans (UK Biobank prospective cohort) (HR 0.90, 95%CI 0.84-0.95).

    “OC use was associated with reduced risks of all-cause dementia (HR 0.90, 95%CI 0.84-0.95)”

    HumansUK Biobank prospective cohortfemalesn = 273,069

    Association between exogenous hormone use and dementia: A prospective cohort study and synthetic analysis

    Maturitas

More on Dementia

Cardiovascular disease

upin humans2HR 1.11

2 studies
  1. Oral contraceptives are associated with cardiovascular disease in humans (Adjusted HR 1.11, 95% CI 1.01–1.22; P for trend = 0.007).

    “Compared with non-users, oral contraceptives (OC) users (≥1 year) had an increased risk of CVD (1.11, 1.01-1.22)”

    HumansPre-menopausal women; compared with non-users; adjusted for cardiovascular and reproductive risk factorsUse for ≥1 year; mean follow-up of 8.3 yearsfemalesn = 1,088,992

    Association of reproductive factors with cardiovascular disease risk in pre-menopausal women: nationwide population-based cohort study

    European journal of preventive cardiology

  2. Oral contraceptives are associated with cardiovascular disease in humans (Current or recent use; mainly among smokers).

    “Current or recent oral contraceptive use is associated with a higher risk of cardiovascular disease (mainly among smokers)”

    ReviewCurrent or recent use; mainly among smokersfemales

    Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses' Health Study

    American journal of public health

More on Cardiovascular disease

Incident osteoporosis

upin humans1HR 1.04

1 study
  1. Oral contraceptives are associated with incident osteoporosis in humans (Postmenopausal women; compared with never use) (HR 1.04 for both duration categories; all P < 0.001).

    “OC use of any duration was associated with a modestly higher risk than never use”

    HumansPostmenopausal women; compared with never useAny duration of usefemales

    Longer reproductive span linked to lower osteoporosis risk

    Human reproduction open

More on Incident osteoporosis

Osteoprotegerin

upin humans1

1 study
  1. Oral contraceptives are associated with osteoprotegerin in humans (Active pill versus withdrawal phase).

    “osteoprotegerin (OPG) was higher in APP than WP.”

    Human trialActive pill versus withdrawal phasebloodfemales

    Bone biomarker concentrations at baseline and 24 h after resistance and interval running exercise in eumenorrheic females and oral contraceptive users

    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

More on Osteoprotegerin

Osteocalcin

downin humans1

1 study
  1. Oral contraceptives are associated with osteocalcin in humans (Endurance-trained oral contraceptive users; active pill versus withdrawal phase).

    “lower concentrations in endurance-trained OC users during APP versus WP.”

    Human trialEndurance-trained oral contraceptive users; active pill versus withdrawal phasebloodfemales

    Bone biomarker concentrations at baseline and 24 h after resistance and interval running exercise in eumenorrheic females and oral contraceptive users

    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

More on Osteocalcin

Glaucoma suspect

downin humans1

1 study
  1. Oral contraceptives are linked with a lower risk of glaucoma suspect in humans (P < 0.001).

    “Long-term oral contraceptive use (n = 5795) was associated with a lower risk of glaucoma suspect diagnosis (P < 0.001).”

    Humanslong-termn = 5,795

    Association of glaucoma diagnosis with sex hormone-related diagnoses and hormone-replacement therapy within a national U.S. database

    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

More on Glaucoma suspect

All 39

Has oral contraceptives been tested in people?

0 of 7 about aging

Yes: 8 trials and 81 observational studies in people have been published, and 7 trials are registered.

In trials

Trial sponsors

Latest

Dec 2025: 9Jan 2026: 5Feb 2026: 8Mar 2026: 5Apr 2026: 4May 2026: 4Jun 2026: 3Jul 2026: 1Aug 2026: 2Sep 2026: 2Oct 2026: 1Nov 2026: 549 papers in 12 months
Human Reproduction Open

Longer reproductive span linked to lower osteoporosis risk

Compared with under 30 years, at least 40 years between first period and menopause was linked to lower osteoporosis risk (hazard ratio 0.82).Compared with under 30 years, at least 40 years between first period and menopause was linked to lower osteoporosis risk (hazard ratio 0.82).

Cohort · 2,147,384 peopleOsteoporosis

See all 119 papers on oral contraceptives